Article

Rational design of a fusion partner for membrane protein expression in E. coli

New England Biolabs, Inc. Gene Expression Division, Ipswich, Massachusetts 01938, USA.
Protein Science (Impact Factor: 2.86). 08/2009; 18(8):1735-44. DOI: 10.1002/pro.189
Source: PubMed

ABSTRACT We have designed a novel protein fusion partner (P8CBD) to utilize the co-translational SRP pathway in order to target heterologous proteins to the E. coli inner membrane. SRP-dependence was demonstrated by analyzing the membrane translocation of P8CBD-PhoA fusion proteins in wt and SRP-ffh77 mutant cells. We also demonstrate that the P8CBD N-terminal fusion partner promotes over-expression of a Thermotoga maritima polytopic membrane protein by replacement of the native signal anchor sequence. Furthermore, the yeast mitochondrial inner membrane protein Oxa1p was expressed as a P8CBD fusion and shown to function within the E. coli inner membrane. In this example, the mitochondrial targeting peptide was replaced by P8CBD. Several practical features were incorporated into the P8CBD expression system to aid in protein detection, purification, and optional in vitro processing by enterokinase. The basis of membrane protein over-expression toxicity is discussed and solutions to this problem are presented. We anticipate that this optimized expression system will aid in the isolation and study of various recombinant forms of membrane-associated protein.

Full-text

Available from: James C Samuelson, May 05, 2014
0 Followers
 · 
85 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The transmembrane subunit (gp41) of the envelope glycoprotein of HIV-1 associates non-covalently with the surface subunit (gp120) and together they play essential roles in viral mucosal transmission and infection of target cells. The membrane proximal region (MPR) of gp41 is highly conserved and contains epitopes of broadly neutralizing antibodies. The transmembrane (TM) domain of gp41 not only anchors the envelope glycoprotein complex in the viral membrane but also dynamically affects the interactions of the MPR with the membrane. While high-resolution X-ray structures of some segments of the MPR were solved in the past, they represent the post-fusion forms. Structural information on the TM domain of gp41 is scant and at low resolution. Here we describe the design, expression and purification of a protein construct that includes MPR and the transmembrane domain of gp41 (MPR-TMTEV6His), which reacts with the broadly neutralizing antibodies 2F5 and 4E10 and thereby may represent an immunologically relevant conformation mimicking a pre-hairpin intermediate of gp41. The expression level of MPR-TMTEV6His was improved by fusion to the C-terminus of Mistic protein, yielding ˜1 mg of pure protein per liter. The isolated MPR-TMTEV6His protein was biophysically characterized and is a monodisperse candidate for crystallization. This work will enable further investigation into the structure of MPR-TMTEV6His, which will be important for the structure-based design of a mucosal vaccine against HIV-1.
    Protein Science 11/2014; 23(11). DOI:10.1002/pro.2540 · 2.86 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Escherichia coli is by far the most widely used bacterial host for the production of membrane proteins. Usually, different strains, culture conditions and production regimes are screened for to design the optimal production process. However, these E. coli-based screening approaches often do not result in satisfactory membrane protein production yields. Recently, it has been shown that (i) E. coli strains with strongly improved membrane protein production characteristics can be engineered or selected for, (ii) many membrane proteins can be efficiently produced in E. coli-based cell-free systems, (iii) bacteria other than E. coli can be used for the efficient production of membrane proteins, and, (iv) membrane protein variants that retain functionality but are produced at higher yields than the wild-type protein can be engineered or selected for. This article is part of a Special Issue entitled:Protein trafficking & Secretion.
    Biochimica et Biophysica Acta 11/2013; 1843(8). DOI:10.1016/j.bbamcr.2013.10.023 · 4.66 Impact Factor